Pharma Pricing

Article archives from the Pricing Pricing Society

Embracing the Change: 2020 China NRDL Outlook

China’s 2020 NRDL (National Reimbursement Drug List) process has been unfolding since July this year with a number of new changes and interesting twists. Based on the authors’ experience and observations, as well as ongoing discussions with key players and stakeholders in the industry, they have identified three themes and made five predictions on the likely outcomes of 2020 NRDL process.

Achieving Market Access for a Novel Ultra-Orphan Treatment

This case study outlines how to implement value pricing approaches in the difficult process of pricing a new pharmaceutical product. The process implemented in this project enabled the client to achieve market access in the US and the EU5 (Germany, France, UK, Italy, Spain) for a first-in-class, ultra-orphan oncology therapy.

By |2022-04-11T15:30:52+00:00December 31, 2020|Pharma Pricing, Pricing Articles, Pricing Research|0 Comments
Go to Top